SG11202100320QA - Therapeutic preparations of gamma-delta t cells and natural killer cells and methods for manufacture and use - Google Patents

Therapeutic preparations of gamma-delta t cells and natural killer cells and methods for manufacture and use

Info

Publication number
SG11202100320QA
SG11202100320QA SG11202100320QA SG11202100320QA SG11202100320QA SG 11202100320Q A SG11202100320Q A SG 11202100320QA SG 11202100320Q A SG11202100320Q A SG 11202100320QA SG 11202100320Q A SG11202100320Q A SG 11202100320QA SG 11202100320Q A SG11202100320Q A SG 11202100320QA
Authority
SG
Singapore
Prior art keywords
cells
delta
gamma
manufacture
methods
Prior art date
Application number
SG11202100320QA
Other languages
English (en)
Inventor
Concetta Quintarelli
Angelis Biagio De
Franco Locatelli
Original Assignee
Ospedale Pediatrico Bambino Gesù Opbg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ospedale Pediatrico Bambino Gesù Opbg filed Critical Ospedale Pediatrico Bambino Gesù Opbg
Publication of SG11202100320QA publication Critical patent/SG11202100320QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0646Natural killers cells [NK], NKT cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/47Brain; Nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48Blood cells, e.g. leukemia or lymphoma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4613Natural-killer cells [NK or NK-T]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/463Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631Chimeric Antigen Receptors [CAR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/464402Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411Immunoglobulin superfamily
    • A61K39/464412CD19 or B4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/464469Tumor associated carbohydrates
    • A61K39/464471Gangliosides, e.g. GM2, GD2 or GD3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]
    • C12N2501/2301Interleukin-1 (IL-1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]
    • C12N2501/2315Interleukin-15 (IL-15)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/515CD3, T-cell receptor complex
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/53CD2
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
SG11202100320QA 2018-07-26 2019-07-25 Therapeutic preparations of gamma-delta t cells and natural killer cells and methods for manufacture and use SG11202100320QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862703654P 2018-07-26 2018-07-26
PCT/EP2019/070125 WO2020021045A2 (fr) 2018-07-26 2019-07-25 Préparations thérapeutiques de lymphocytes t gamma-delta et de cellules tueuses naturelles et méthodes de préparation et d'utilisation

Publications (1)

Publication Number Publication Date
SG11202100320QA true SG11202100320QA (en) 2021-02-25

Family

ID=67847672

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202100320QA SG11202100320QA (en) 2018-07-26 2019-07-25 Therapeutic preparations of gamma-delta t cells and natural killer cells and methods for manufacture and use

Country Status (8)

Country Link
EP (1) EP3827074A2 (fr)
JP (1) JP7565271B2 (fr)
KR (1) KR20210042119A (fr)
CN (1) CN112912494A (fr)
AU (1) AU2019311290A1 (fr)
CA (1) CA3106056A1 (fr)
SG (1) SG11202100320QA (fr)
WO (1) WO2020021045A2 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10253316B2 (en) 2017-06-30 2019-04-09 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
US11293021B1 (en) 2016-06-23 2022-04-05 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
US10557216B2 (en) 2018-04-24 2020-02-11 Inscripta, Inc. Automated instrumentation for production of T-cell receptor peptide libraries
US10858761B2 (en) 2018-04-24 2020-12-08 Inscripta, Inc. Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
CA3108767A1 (fr) 2018-06-30 2020-01-02 Inscripta, Inc. Instruments, modules et procedes pour une detection amelioree de sequences editees dans des cellules vivantes
US11142740B2 (en) 2018-08-14 2021-10-12 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
US11214781B2 (en) 2018-10-22 2022-01-04 Inscripta, Inc. Engineered enzyme
CN109517793B (zh) * 2018-11-30 2022-05-10 广州长峰生物技术有限公司 一种NK细胞和γδT细胞共培养的建立方法
AU2020247900A1 (en) 2019-03-25 2021-11-04 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
US11001831B2 (en) 2019-03-25 2021-05-11 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
AU2020288623A1 (en) 2019-06-06 2022-01-06 Inscripta, Inc. Curing for recursive nucleic acid-guided cell editing
WO2021102059A1 (fr) 2019-11-19 2021-05-27 Inscripta, Inc. Procédés pour augmenter l'édition observée dans des bactéries
US11008557B1 (en) 2019-12-18 2021-05-18 Inscripta, Inc. Cascade/dCas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
CA3157061A1 (fr) 2020-01-27 2021-08-05 Christian SILTANEN Modules d'electroporation et instrumentation
US20210238535A1 (en) * 2020-02-02 2021-08-05 Inscripta, Inc. Automated production of car-expressing cells
WO2021221766A2 (fr) * 2020-02-19 2021-11-04 Barron Annelise E Procédé de traitement du cancer par régulation à la hausse de l'expression du gène de la cathélicidine et infusion de cellules tueuses naturelles
US20210332388A1 (en) 2020-04-24 2021-10-28 Inscripta, Inc. Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells
US11787841B2 (en) 2020-05-19 2023-10-17 Inscripta, Inc. Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli
EP4214314A4 (fr) 2020-09-15 2024-10-16 Inscripta Inc Édition par crispr pour incorporer des plaques d'amarrage d'acide nucléique dans des génomes de cellules vivantes
US11512297B2 (en) 2020-11-09 2022-11-29 Inscripta, Inc. Affinity tag for recombination protein recruitment
WO2022109477A1 (fr) * 2020-11-23 2022-05-27 University Of Florida Research Foundation, Incorporated Utilisation de facteurs de croissance de type insuline avec des cytokines à chaîne gamma pour induire une prolifération homéostatique de lymphocytes
CN112501127B (zh) * 2020-12-21 2023-10-10 广东昭泰细胞生物科技有限公司 一种重编程nk细胞的培养方法
EP4271802A1 (fr) 2021-01-04 2023-11-08 Inscripta, Inc. Nucléases mad
US11332742B1 (en) 2021-01-07 2022-05-17 Inscripta, Inc. Mad nucleases
US11884924B2 (en) 2021-02-16 2024-01-30 Inscripta, Inc. Dual strand nucleic acid-guided nickase editing
AU2022270361A1 (en) 2021-05-05 2023-11-16 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
GB202115389D0 (en) * 2021-10-26 2021-12-08 XNK Therapeutics AB Methods
CN114107200B (zh) * 2021-11-29 2023-04-21 华东师范大学 一种高纯度CD56+γδT细胞及其制备方法和用途
US20240228959A9 (en) * 2022-10-10 2024-07-11 Kite Pharma, Inc. Large scale car-t immune cell manufacturing method utilizing lentiviral vector transfection
CN115651903B (zh) * 2022-11-14 2023-03-17 四川新生命干细胞科技股份有限公司 高杀伤力的免疫细胞群及其培养方法、试剂组合物和应用
WO2024129862A2 (fr) * 2022-12-13 2024-06-20 Dana-Farber Cancer Institute, Inc. Modulateurs de points de contrôle pour améliorer l'immunothérapie

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1317108B1 (it) 2000-12-06 2003-05-26 Philogen Srl Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso.
JP2010220479A (ja) * 2007-06-15 2010-10-07 Medeinetto:Kk Nk細胞の培養方法及びnk細胞の利用
ES2643387T3 (es) * 2011-05-19 2017-11-22 Instituto De Medicina Molecular Estirpe celular de linfocitos que comprende células gama-delta, composición y método de producción de la misma
IL253149B2 (en) * 2014-12-29 2023-11-01 Novartis Ag Methods for preparing cells expressing a chimeric receptor antigen
CN109476722A (zh) * 2015-07-21 2019-03-15 诺华股份有限公司 用于改善免疫细胞的功效和扩张的方法
WO2017197347A1 (fr) * 2016-05-12 2017-11-16 Adicet Bio, Inc. Procédés de multiplication sélective de populations de lymphocytes t γδ et compositions associées

Also Published As

Publication number Publication date
JP7565271B2 (ja) 2024-10-10
WO2020021045A9 (fr) 2021-03-04
JP2021532829A (ja) 2021-12-02
CN112912494A (zh) 2021-06-04
WO2020021045A3 (fr) 2020-03-12
WO2020021045A2 (fr) 2020-01-30
AU2019311290A1 (en) 2021-01-28
CA3106056A1 (fr) 2020-01-30
EP3827074A2 (fr) 2021-06-02
KR20210042119A (ko) 2021-04-16

Similar Documents

Publication Publication Date Title
SG11202100320QA (en) Therapeutic preparations of gamma-delta t cells and natural killer cells and methods for manufacture and use
IL275433A (en) Artificial antigen-presenting cells and methods of use
IL288373A (en) flt3l-fc fusion proteins and methods of use
EP3621648A4 (fr) Protéines trispécifiques ciblant la msln et procédés d'utilisation
EP3694529A4 (fr) Protéines trispécifiques et méthodes d'utilisation
IL282757A (en) Methods for selecting and stimulating cells and apparatus therefor
ZA202006905B (en) Gene therapy constructs and methods of use
EP3749344A4 (fr) Procédés d'utilisation thérapeutique d'exosomes et d'arn y
EP4034640A4 (fr) Cellules immunitaires génétiquement éditées et procédés de traitement
EP3506917A4 (fr) Bactéries génétiquement modifiées sécrétant des protéines thérapeutiques et procédés d'utilisation de celles-ci
IL288310A (en) Modulators of cot and methods of using them
EP3891175A4 (fr) Protéines modifiées et méthodes de traitement associées
EP3678701A4 (fr) Compositions protéiques thérapeutiques et procédés de préparation et d'utilisation de celles-ci
IL292319A (en) Cell selection and/or stimulation devices and methods of use
EP3920956A4 (fr) Procédés d'utilisation de protéines thérapeutiques glycopolysialylées
IL291180A (en) Bee vaccines and methods of use
EP3856211A4 (fr) Procédés d'isolement et de culture de cellules progénitrices rétiniennes humaines
EP3313427A4 (fr) Peptides thérapeutiques et leurs procédés d'utilisation
IL283916A (en) Antibodies against human complement factor c2b, and methods of using them
EP4025585A4 (fr) Peptides modifiés et procédés d'utilisation associés
EP3802797A4 (fr) Procédés de fabrication de cellules tueuses naturelles et leurs utilisations
EP3790603A4 (fr) Matériau de type hydrogel thérapeutique et ses procédés d'utilisation
EP3650461A4 (fr) Nouveau peptide présentant un effet de libération des cellules souches hématopoïétiques dans le sang et un effet thérapeutique contre l'ostéoporose et son utilisation
SG11201909851SA (en) Peptide for inducing regeneration of tissue, and use thereof
EP4031174A4 (fr) Vaccins peptidiques anti-pd-l1 humain et leurs procédés d'utilisation